Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, With a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Alopecia Areata
Conditions
Interventions
Etrasimod
Etrasimod
+1 more
Locations
42
United States
Investigate MD
Scottsdale, Arizona, United States
Dermatology Trial Associates
Bryant, Arkansas, United States
California Dermatology & Clinical Research Institute
Encinitas, California, United States
First OC Dermatology
Fountain Valley, California, United States
University of California,Irvine
Irvine, California, United States
Prospect Optometry
Lomita, California, United States
Start Date
July 29, 2020
Primary Completion Date
June 7, 2023
Completion Date
June 7, 2023
Last Updated
June 26, 2024
NCT06826196
NCT06562270
NCT07133308
NCT06327581
NCT07023302
NCT07152119
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions